Reid Hoffman on intelligent risk
From Investing in the Future – Greylock's Reid Hoffman and Sarah Guo at CNBC @Work Summit · · CNBC Events
“Well i think one of the frameworks that i usually work with my portfolio companies is how do you take intelligent risk because actually in fact taking risks can be one of the things that's differential like you adopt a platform before your competitors do, use go to market, you return certain parts of speed or growth or investing to your business before they do because you say wait i think we're going to see a resurgence in our market whether it's travel or other kinds of things there's ways that you might be doing and saying i'm going to take a risk and go early in order to do that.”
On , Reid Hoffman, Co-Founder at LinkedIn, spoke about intelligent risk during Investing in the Future – Greylock's Reid Hoffman and Sarah Guo at CNBC @Work Summit on CNBC Events.
About Reid Hoffman
Reid Hoffman, co-founder of LinkedIn and a partner at Greylock, has been making public appearances discussing artificial intelligence, cryptocurrency, and healthcare. At the Consensus 2026 conference, Hoffman stated that he bought his first Bitcoin in 2014 and has not sold any since, and he argued that as AI agents outnumber people on the internet, crypto becomes necessary for trust and identity. He said he has returned to crypto with "fresh conviction" and mentioned purchasing a CryptoPunk. At WIRED Health, Hoffman said that if a patient or doctor is not using frontier AI models as a second opinion for serious conditions, he believes they are "bordering on committing malpractice." He also expressed hope that within ten years, every major disease will have target molecules that could make a serious difference. In other appearances, Hoffman discussed the future of work and AI. At the Science x AI Summit, he said that "no one should really be an individual contributor" and that people should instead be "a manager of agents." On the Prof G Markets podcast, he described the transition to an AI-driven economy as "challenging" and noted that it is faster than previous technological shifts. Hoffman also discussed his role as co-founder of Manas AI, an AI-driven drug discovery company, and reiterated his view that AI can expand human capability, a theme he explored in his book "Superagency."